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Background
Gag-specific CD8 T-cell responses have repeatedly been
associated with lower viremia. However, no functional
mechanism has been determined thus far. By using an
array of cellular assays we aimed to identify characteristics
of CD8 T-cells, which are associated with enhanced anti-
viral control.
Methods
26 patients with broad (> 6) or narrow (< 1) gag responses
assessed by IFN-γ Elispot were selected from 288
untreated HIV-1 clade C-infected South Africans. We con-
trolled for disease progression and total numbers of HIV
specific CD8 T-cells. Infected or uninfected CD4 T-cells
from both groups were co-cultured with autologous
unstimulated CD8 T-cells. HIV-1 replication was meas-
ured by p24 ELISA. Phenotypes and cytokine profiles were
assessed by flow. Proliferation was measured by CFSE
dilution.
Results
Viral load was lower in individuals that generate broad
gag responses compared to persons with few or no Gag-
specific responses. CD8 T-cells from high gag responders
suppressed HIV-1 replication more potently than those
from low gag responders (mean Log10 inhibition: 1.38 vs
0.5, p < 0.004). Furthermore, CD8 T-cells from high gag
responders secreted a more 2 and 3- functional cytokine
profile than low gag responders, who mainly exhibited
mono-functional CD8 T-cells. The ability to respond poly-
functionally was significantly correlated with the ability to
inhibit viral replication in vitro. Furthermore, CD8 T-cells
from high gag responders showed a stronger proliferative
capacity. However, no difference in the maturation status
of HIV-specific CD8 T-cells was observed.
Conclusion
Subjects who target more epitopes in gag exhibit lower
viral loads than subjects who target this protein less. This
enhanced viral control is associated with an elevated CD8
T-cell inhibitory capacity, enhanced proliferation, poly-
functional cytokine secretion, but no difference in the
maturation status of CD8 T-cells. This data indicates that
it is not the phenotype but the specificity and functional
capacity that are indicative of effective antiviral CD8 T-cell
function.
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